You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TKI Resistance

Showing 1 - 25 of 8,510
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

Not yet recruiting
  • Lung Cancer
  • +4 more
  • (no location specified)
Sep 15, 2023

Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation Trial in Changsha (Gemcitabine platinum combined with erlotinib)

Recruiting
  • Carcinoma, Non-Small Cell Lung
  • EGFR Gene Mutation
  • Gemcitabine platinum combined with erlotinib
  • Changsha, Hunan, China
    Hunan Province Tumor Hospital
Feb 28, 2022

Safety Trial in GuangZhou (Almonertinib combine with Pyrrolitinib)

Recruiting
  • Safety
  • Almonertinib combine with Pyrrolitinib
  • GuangZhou, Guang Dong, China
    Sun Yat-sen University Cancer Center
Mar 4, 2021

Bronchial Tumors Trial in Germany, Spain (EGF816, Trametinib)

Recruiting
  • Bronchial Neoplasms
  • Cologne, Germany
  • +6 more
Nov 2, 2022

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Innate CD8+ T Cells and Evolution of Tyrosine Kinase Inhibitor

Recruiting
  • Leukemia
  • +3 more
  • Phenotyping of total and innate CD8+T cells by flow cytometry
  • Nîmes, Gard, France
    CHU de Nîmes
Jul 19, 2021

Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial in Changsha (Genomic profiles detection,

Recruiting
  • Lung Cancer, Non-small Cell
  • +4 more
  • Genomic profiles detection
  • circulating tumor DNA detection
  • Changsha, Hunan, China
    Department of Oncology, The Second Xiangya Hospital, Central Sou
Oct 25, 2022

Combination of Osimertinib and Aspirin to Treat 1st Generation

Unknown status
  • Non-Small Cell Lung Cancer Stage IIIB
  • +2 more
  • (no location specified)
Jul 22, 2020

NSCLC Trial in Worldwide (Tepotinib, Gefitinib, Pemetrexed)

Completed
Has Results
  • Non-small Cell Lung Cancer
  • Beijing, China
  • +43 more
Oct 13, 2022

Double-dose Furmonertinib in Treatment of Slow

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • (no location specified)
Oct 31, 2023

Plasma NGS for Assessment, Characterization, Evaluation of ALK

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Plasma Next Generation Sequencing (NGS)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 26, 2023

Brain Tumor Trial in Houston (tepotinib, tepotinib plus osimertinib)

Not yet recruiting
  • Brain Tumor
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Combination of Osimertinib and Aspirin to Treat Osimertinib

Unknown status
  • Non-Small Cell Lung Cancer Stage IIIB
  • +2 more
  • (no location specified)
Jul 22, 2020

According to Molecular Identification at Diagnosis

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Next Generation Sequencing (DNA and RNA)
  • (no location specified)
Oct 28, 2022

Metabolic Alternation and Clinicohematological Characteristic in

Not yet recruiting
  • CML, Chronic Phase
  • Tyrosine kinase inhibitor
  • (no location specified)
Nov 6, 2023

NSCLC Trial (Lazertinib group)

Not yet recruiting
  • NSCLC
  • Lazertinib group
  • (no location specified)
Jul 14, 2022

Resistance to Tyrosine Kinase Inhibitor Osimertinib and

Recruiting
  • Lung Cancer
  • Blood Samples
  • Lorient, France
  • +3 more
Apr 26, 2022

Outcomes of Tyrosine Kinase Inhibitor(TKI)Stopping in Chronic

Recruiting
  • Folate
  • +2 more
    • Nantong, China
      Affliated Hospital of Nantong University
    Dec 13, 2021

    GIST: Assessment of Tumor Mutations and TKI Plasma Exposure

    Recruiting
    • Gastro-intestinal Stromal Tumor
    • Vena puncture for blood collection
    • Tumor biopsy
    • Amsterdam, Netherlands
    • +4 more
    May 17, 2022

    Leukemia, Myeloid, Chronic-Phase Trial in Germany (Ponatinib)

    Active, not recruiting
    • Leukemia, Myeloid, Chronic-Phase
    • Halle (Saale), Saxony-Anhalt, Germany
    • +9 more
    Sep 9, 2022

    Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)

    Recruiting
    • Non-small-cell Lung Carcinoma
    • Beijing, China
      Cancer Hospital, Chinese Academy of Medical Sciences
    May 11, 2023

    NSCLC Trial in Shanghai (Pembrolizumab, Lenvatinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Department of Oncology, Shanghai Lung Cancer Center, Shanghai Ch
    Dec 7, 2021

    Lung Cancer Trial in Shanghai (Miseq sequencer)

    Completed
    • Lung Cancer
    • Miseq sequencer
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Dec 6, 2019

    Resistance-associated Mutations in Metastatic Lung Cancer

    Recruiting
    • Lung Cancer
    • Liquid biopsy
    • Monza, MB, Italy
      Fondazione IRCCS San Gerardo dei Tintori
    Oct 10, 2023

    Non Small Cell Lung Cancer Metastatic Trial in Worldwide (Osimertinib, Bevacizumab)

    Active, not recruiting
    • Non Small Cell Lung Cancer Metastatic
    • Dublin, Ireland
    • +24 more
    Aug 23, 2022